Related by context. All words. (Click for frequent words.) 86 Receives Orphan Drug Designation 86 Meets Primary Endpoint 86 Presents Preclinical Data 85 Preclinical Data 85 Clinical Trial Results 85 Phase 2b Trial 85 Phase 2b Clinical Trial 85 Completes Patient Enrollment 84 Files IND 84 Phase 2a Trial 84 Initiates Clinical Trial 83 Phase III Clinical Trial 83 Novel Oral 83 Present Preclinical Data 83 Completes Enrollment 83 Phase IIb Trial 83 Phase III Trial 83 Improves Survival 83 Patients Treated With 83 Investigational Treatment 82 Drug Shows Promise 82 Patient Enrollment 82 FDA Accepts 82 Demonstrates Significant 82 Mouse Model 82 Submits NDA 82 Study Evaluating 82 Phase IIb Clinical Trial 82 Initiates Phase II 82 Kinase Inhibitor 82 Phase 2a Clinical Trial 82 Systemic Delivery 82 Investigational Compound 82 Antitumor Activity 82 Drug Fails 82 Shows Promising 81 FDA Okays 81 Presents Positive 81 Previously Treated 81 FDA Clears 81 Prolongs Survival 81 Phase IIa Clinical Trial 81 Lung Cancer Drug 81 Epilepsy Drug 81 Initiates Clinical 81 IND Application 81 Cholesterol Lowering Drug 81 Lupus Drug 81 Anti Tumor Activity 81 Generic Version 81 Transdermal Patch 81 Anti Tumor 81 JAK Inhibitor 80 Demonstrates Positive 80 Initiates Phase III 80 Monoclonal Antibody 80 Patent Covering 80 Receives Milestone Payment 80 Advanced Melanoma 80 Novel Mechanism 80 Initiates Clinical Trials 80 Pivotal Study 80 Phase III Trials 80 Combination Treatment 80 Well Tolerated 80 Receives Approvable Letter 80 NDA Submission 80 Adjuvant Treatment 80 Arthritis Drug 80 Improves Outcomes 80 Osteoporosis Drug 80 Orally Active 80 FDA Approvals 79 Receptor Agonist 79 Initiate Phase 79 Significantly Improves 79 Investigational Agent 79 Granted Orphan Drug 79 Initiate Clinical Trial 79 Successfully Completes Phase 79 Demonstrates Potent 79 Rheumatoid Arthritis Drug 79 Trial Evaluating 79 Shows Promise Against 79 Shows Promise 79 Initiates Phase 79 II Clinical Trial 79 Mylan Receives Approval 79 Pooled Analysis 79 Clinical Trial Evaluating 79 Achieves Primary Endpoint 79 Gout Drug 79 Recombinant Human 79 Drug Resistant 79 Novel Antibiotic 79 Survival Benefit 79 Single Dose 79 Blood Pressure Drug 79 Demonstrates Efficacy 79 JAK2 Inhibitor 78 Fast Track Status 78 Commences Phase 78 Pharmacokinetic Study 78 Demonstrates Potential 78 Preclinical Study 78 Drug Combo 78 Begins Dosing 78 Demonstrated Significant 78 Presents Preclinical 78 Protease Inhibitor 78 RNAi Therapeutic 78 Phase 2b Study 78 Severe Sepsis 78 Pivotal Phase III 78 Tumor Targeting 78 Tezampanel 78 Milestone Payment 78 Study Showed 78 Migraine Drug 78 Hsp# Inhibitor 78 Develop Novel 78 Combination REOLYSIN R 78 Initiates Enrollment 78 Disease Modifying 78 Inhibits 78 Is Well Tolerated 78 Phase 1b Clinical Trial 78 Teva Provides Update 78 Shows Efficacy 78 Chronic Hepatitis C 78 First Patient Dosed 78 Receives Orphan Drug 78 Topical Treatment 78 Diabetic Neuropathy 78 Effectively Treats 78 Oral Fingolimod 78 Vaccine Adjuvant 78 Anticancer Activity 78 Collaborators Present 78 Significantly Improved 77 Novel Compound 77 Initiates Dosing 77 Pivotal Phase 77 Hypertensive Patients 77 Cholesterol Drug 77 RNAi Therapeutics 77 HDAC Inhibitor 77 Tumor Growth 77 Prostate Cancer Vaccine 77 Vaccine Candidate 77 Study Demonstrates 77 Psoriasis Drug 77 Renal Cell Carcinoma 77 Dose Ranging Study 77 Nicotine Vaccine 77 Receptor Antagonist 77 Patients Suffering 77 Files Investigational 77 Statistically Significant 77 Combination Therapy 77 Long Term Efficacy 77 Adjunctive Therapy 77 Tyrosine Kinase Inhibitor 77 Adjuvant Chemotherapy 77 Disease Progression 77 Generic Versions 77 Schizophrenia Drug 77 Hormone Refractory Prostate Cancer 77 PRN FDA Approves 77 FDA Approves 77 Announces Initiation 77 Patients Treated 77 Therapeutic Antibody 77 Initiates Phase 2b 77 Treated Patients 77 IND Filing 77 Investigational Oral 77 Randomized Phase 77 Newly Diagnosed Multiple Myeloma 77 Fungal Infections 77 Treating Chronic 77 Therapeutic Potential 77 Licenses Novel 77 Patients Receiving 76 Treatment Reduces 76 Small Molecule 76 Novel Inhibitor 76 Improve Survival 76 Spectrum Pharmaceuticals Announces 76 Receives FDA Clearance 76 Reports Preclinical Data 76 Shows Statistically Significant 76 Announces FDA Clearance 76 Inhaled Corticosteroids 76 Attenuates 76 Lowers Risk 76 Low Dose 76 Proves Effective 76 Protein Linked 76 Investigational Drug 76 Interferon Beta 76 Adjuvant Therapy 76 Diabetic Nephropathy 76 Gene Mutation 76 Gene Linked 76 HCV Protease Inhibitor 76 Confirmatory Phase 76 Myeloma Patients 76 Patients Enrolled 76 Data Suggest 76 Infected Patients 76 Resistant Hypertension 76 Gene Variant 76 Therapeutic Vaccine 76 Oral Formulation 76 Medoxomil 76 Multiple Myeloma Patients 76 Slow Progression 76 Submits IND 76 Initiate Phase III 76 Anti Inflammatory Drug 76 Rheumatoid Arthritis Patients 76 Novel Treatments 76 Pediatric Patients 76 Relapsed Refractory 76 Biomarker Study 76 BioSante Pharmaceuticals Announces 76 Elderly Patients 76 Aurora Kinase 76 Begin Clinical Trials 76 Osteoporosis Treatment 76 Treatment Shows Promise 76 Prophylactic Treatment 76 Controlled Trial 76 Gets FDA Clearance 76 Monotherapy 76 Novel Therapeutic 76 Bosutinib 76 Immunomedics Announces 76 Expanded Indication 75 Rotavirus Vaccine 75 FDA APPROVES 75 Safinamide 75 Complicated Skin 75 Dose Escalation 75 Oral Calcitonin 75 Announces Poster Presentations 75 Breast Cancer Recurrence 75 Slows Progression 75 Phase Ib Clinical Trial 75 Double Blind Placebo 75 Gene Variants 75 Appears Safe 75 Prodrug 75 Therapy Improves 75 Test Detects 75 Molecular Diagnostic Test 75 Interferon Alpha 75 Demonstrates Statistically Significant 75 First Patient Enrolled 75 Significantly Reduces 75 Vicriviroc 75 Mg Usa 75 Submits Biologics License Application 75 Treatment Naïve 75 Prostate Cancer Patients 75 Lung Cancer Trial 75 Anticancer Drug 75 Pivotal Trial 75 Pivotal Trials 75 Blood Thinner 75 Improved Survival 75 Refractory Hodgkin Lymphoma 75 Pafuramidine 75 Polymerase Inhibitor 75 Immune Responses 75 Mouse Models 75 Proven Effective 75 Suppresses 75 Receives Positive Opinion 75 Inhaled Insulin 75 Genes Linked 75 Announces Tentative Approval 75 Anti Inflammatory 75 Humanized Anti 75 Earns Milestone Payment 75 Anticancer Agent 75 Commence Phase 75 Antifungal 75 Beneficial Effects 75 Antitumor 75 Levels Linked 75 Induces 75 Clinical Trial Data 75 Metastatic Melanoma 75 Personalized Immunotherapy 75 Kidney Function 75 Interferon Gamma 75 Receives Fast Track 75 Combo Therapy 75 Metabolic Disorder 75 Pulmonary Arterial Hypertension 75 FDA Approves Drug 75 Fewer Side Effects 75 Reduces Risk 75 Antiviral Drugs 75 Efficacy Trial 75 Anticancer Compound 75 Significantly Reduced 75 Increases Risk 74 Metastatic Colorectal Cancer 74 Autologous Stem Cell Transplantation 74 Patients Undergoing 74 Announce License Agreement 74 Drug Prevents 74 Breast Cancer Cells 74 Treatment Resistant 74 Node Positive 74 Aliskiren 74 Holds Promise 74 Vitro Activity 74 Lanthanum Carbonate 74 Advanced Prostate Cancer 74 Unfractionated Heparin 74 Treatment Regimen 74 Liver Toxicity 74 Submits Supplemental 74 Peginterferon Alfa 2a 74 Cocaine Addiction 74 Patient Enrolment 74 Dendritic Cells 74 Versus Placebo 74 Intravenous Formulation 74 Sangamo BioSciences Announces 74 Advanced Colorectal Cancer 74 Synthetic Peptide 74 Malaria Vaccine 74 Phase III Clinical Trials 74 Generic Version Of 74 Treatment Naïve Patients 74 Inflammatory Arthritis 74 Plaque Psoriasis 74 Clinical Outcome 74 Companion Diagnostic 74 Showed Significant 74 Nucleoside 74 HER2 Positive Breast Cancer 74 Relapsing Multiple Sclerosis 74 Stem Cell Treatment 74 Heart Failure Patients 74 First Patient Treated 74 Targeted Therapies 74 AnaSpec Introduces 74 Liposomal 74 Pharmacokinetics PK 74 Benign Prostatic Hyperplasia 74 TNF Blockers 74 Patents Covering 74 Taro Receives 74 SPRYCEL ® 74 MEK Inhibitor 74 Desvenlafaxine Succinate 74 Flamel Technologies Announces 74 Genes Involved 74 Antiviral Activity 74 Milestone Payments 74 Completes Dosing 74 Antigen Specific 74 Diabetic Patients 74 Reveals Positive 74 Successfully Treated 74 PEGylated Fab fragment 74 Kinase Inhibitors 74 Weight Loss Drug 74 Anthracycline 74 Collaborators Publish 74 Therapeutic Competitors Companies 74 Announces Publication 74 Telaprevir VX 74 Neoadjuvant Chemotherapy 74 Presents Positive Preclinical 74 Protein Involved 74 Vaccine Protects Against 74 Controlled Study 74 Plus Ribavirin 74 pralatrexate injection folate analogue 73 Confirms Efficacy 73 HER2 Positive 73 Phase IIa Trial 73 Cutaneous T 73 Chronic Hepatitis B 73 PDUFA Date 73 Reacquires 73 Phospholipase A2 73 Commercialize 73 Receive Milestone Payment 73 Kidney Transplant Patients 73 Signaling Pathway 73 Clinical Efficacy 73 Ecallantide 73 Positive Opinion 73 AVI BioPharma Announces 73 Asthma Treatment 73 Potentially Fatal 73 Placebo Controlled Trial 73 Allergic Rhinitis 73 non nucleoside inhibitor 73 Potent Antiviral Activity 73 Hematological Malignancies 73 Peginterferon 73 Cholesterol Drugs 73 Immune Cells 73 Preclinical Efficacy 73 Treatment Experienced 73 Reduced Risk 73 Beta Blocker 73 Previously Untreated 73 Sustained Release 73 Predict Risk 73 Successfully Treats 73 Subgroup Analysis 73 Mg Uk 73 Advanced Pancreatic Cancer 73 Multiple Ascending Dose 73 Integrase Inhibitor 73 Diagnostic Tests 73 Oral Mucositis 73 Mimetics 73 Hepatitis B Vaccine 73 Overactive Bladder 73 Chemotherapy Induced 73 Pegylated 73 Renal Cancer 73 Smallpox Vaccine 73 Hypercholesterolemia 73 Hepatitis C Patients 73 Cholesterol Lowering 73 Tablet Formulation 73 Factor Receptor 73 Vaccine Shows Promise 73 Xcytrin R 73 Postmenopausal Osteoporosis 73 Announces Positive 73 Milestone Payment From 73 Soft Tissue Sarcoma 73 Myelodysplastic Syndromes 73 Epidermal Growth Factor Receptor 73 Enrolls First 73 Novel Anti Inflammatory 73 FDA Clearance 73 Patient Treated 73 Cell Transplants 73 Anticancer Drugs 73 Demonstrates Ability 73 Dose Escalation Study 73 Antibody Drug Conjugate 73 Secondary Hyperparathyroidism 73 Efficacious 73 Insulin Resistance 73 Replacement Therapy 73 Metastatic Prostate Cancer 73 Bone Metastases 73 Smooth Muscle 73 Randomized Double blind 73 Elagolix 73 Sign Licensing Agreement 73 Hepatocellular Carcinoma 73 Granulocyte Colony Stimulating Factor 73 Parathyroid Hormone 73 NICE Recommends 73 Knee Osteoarthritis 73 Newly Diagnosed 73 Chemokine Receptor 73 Subtypes 73 Prospective Randomized 73 Phase III Pivotal Trial 73 Advanced Renal Cell 73 Universal Flu Vaccine 73 Sapacitabine 73 Therapeutic Efficacy 73 Phase 2a Study 73 Newly Identified 73 Virus Linked 73 Oral Laquinimod 73 Drug Maker 73 Hepatitis C Treatment 73 Chronic Myeloid Leukemia 73 Lupus Nephritis 72 Oral Spray 72 Therapy Reduces 72 Trodusquemine MSI 72 Submits Response 72 Seasonal Influenza Vaccine 72 Significantly Increases 72 Relapsed Multiple Myeloma 72 Protease Inhibitors 72 Increased Risk 72 FDA Panel Recommends 72 Angiogenic 72 Antisense Drug 72 Preclinical Models 72 Anemia Drug 72 Vaccine Prevents 72 Meta Analysis 72 Identifies Potential 72 Immunotherapeutic 72 Commercialize Novel 72 Bazedoxifene 72 Recurrent Breast Cancer 72 Progressive Multifocal Leukoencephalopathy 72 See CLINICAL PHARMACOLOGY 72 Statin Drugs 72 oral prodrug 72 VIVUS Announces 72 Epratuzumab 72 Supplemental Biologics License Application 72 Patent Issued 72 Cites Positive 72 Launches Generic Version 72 Genetic Mutation 72 Glatiramer Acetate 72 Metastatic Renal Cell Carcinoma 72 Atopic Dermatitis 72 Lung Cancer Patients 72 Naive Patients 72 Therapy Shows Promise 72 Antidepressant Drug 72 Inflammatory Markers 72 Achieves Milestone 72 Randomized Study 72 Cancer Cells 72 TB Vaccine 72 Atypical Hemolytic Uremic Syndrome 72 Progenitor Cells 72 Novel Compounds 72 Osteoporosis Drugs 72 Gene Mutations 72 Anti Clotting Drug 72 Sign License Agreement 72 Genes Identified 72 Fracture Risk 72 Hormone Receptor Positive 72 Oral Insulin 72 Potent Inhibitor 72 Antiviral Therapy 72 Castration Resistant Prostate Cancer 72 Virus Infection 72 Lung Cancer Survival 72 Study Shows Benefits 72 Researchers Identify 72 Gene Therapy Trial 72 Human Monoclonal Antibody 72 Romidepsin 72 Million Milestone Payment 72 Effective Than 72 Antiangiogenic 72 Study Casts Doubt 72 Therapeutic Vaccines 72 Anti Angiogenic 72 Postmenopausal Women 72 Immune Cell 72 Maribavir 72 Chemotherapy Regimen 72 Randomized Clinical Trial 72 Gene Variation 72 Diabetic Foot Ulcer 72 Epilepsy Drugs 72 Abstract Accepted 72 Receives Complete Response 72 Disease IBD 72 Randomized Double Blind 72 Obesity Linked 72 Acute Attacks 72 Shown Effective 72 Files Patent Application 72 Pivotal Clinical Trial 72 Muscle Wasting 72 Inhalation Aerosol 72 Carboplatin Paclitaxel 72 methylnaltrexone bromide 72 Recombinant Protein 72 Aztreonam Lysine 72 Potent Anti 72 Announces Presentation 72 Clinical Study 72 FOLOTYN ® 72 Dose Finding 72 Non Inferiority 72 Immunomodulatory 72 Clinical Study Shows 72 Dasatinib 72 Lymphoid 72 BioElectronics Announces 72 Poorly Controlled 72 Therapeutic Antibodies 72 Chronic Lymphocytic Leukemia 72 Reports Positive 72 Hematological Cancers 72 Brentuximab Vedotin SGN 72 Receives Patent 72 Pharmaceuticals Initiates 72 Treat Anemia 71 Liver Injury 71 Experimental Vaccine 71 Melphalan 71 Extended Release 71 Increased Mortality 71 Left Ventricular Hypertrophy 71 NMDA Receptor 71 Aggressive Prostate Cancer 71 Fulvestrant 71 Adjuvanted 71 Demonstrate Significant 71 Genetic Tests 71 Helps Predict 71 Aflibercept 71 Chronic Sinusitis 71 Vitrasert R 71 Avian Flu Vaccine 71 Entry Inhibitor 71 Aptamer 71 Sustained Efficacy 71 Protein Synthesis 71 Diet Pill 71 Anti Nausea 71 Iloperidone 71 Testosterone Patch 71 Pegloticase 71 Demonstrates Sustained 71 Schizophrenia Treatment 71 AAG geldanamycin analog 71 Topline Results 71 Transdermal Delivery 71 Brain Metastases 71 Tolerability 71 sapropterin dihydrochloride 71 candidates Azedra 71 Clinical Evaluation 71 2 methoxyestradiol 71 Emerging Therapies 71 Cannabinoid 71 Glucocorticoid 71 Fondaparinux 71 Artery Disease 71 Atypical Antipsychotic 71 Liver Tumors 71 Cardiotoxicity 71 Tumor Cells 71 Serious Infections 71 Cervical Cancer Vaccine 71 Dose Response 71 Autoimmune Disease 71 Treatment Naive Patients 71 Viral Load 71 Pharmacyclics Announces 71 R lenalidomide 71 Hemodialysis Patients 71 Analogs 71 Molecular Mechanism 71 Cyclooxygenase 2 71 FDA Approves Generic 71 Sagent Pharmaceuticals Announces 71 Unresectable 71 Tumor Suppressor 71 Antithrombin 71 Oral Interferon 71 Advanced Ovarian Cancer 71 Hepatocellular 71 Systemic Sclerosis 71 Diagnostic Criteria 71 Modulates 71 platform HDL Mimetic 71 Vascular Disrupting Agent 71 IIa Clinical Trial 71 Autoimmune Diseases 71 Cardiovascular Events 71 Calcitonin 71 Effective Treatments 71 Receives Tentative Approval 71 Improve Outcomes 71 Submits Application 71 Anti CD# Antibody 71 Completes Patient Enrolment 71 Eluting Stent 71 Novel Protein 71 Antibiotic Resistant 71 Fluticasone 71 Heartburn Drugs 71 C1 Inhibitor 71 Flagship Product 71 dasatinib Sprycel ® 71 Biogen Genentech 71 Transplant Patients 71 Reduces Pain 71 candidates Azedra TM 71 Hedgehog Pathway 71 Nilotinib 71 Malignant Melanoma 71 Tumor Progression 71 Metabolic Disease 71 TNF Tumor Necrosis Factor 71 Tumor Necrosis Factor 71 Receives SFDA Approval 71 Combination Clinical Trial 71 Cardiac Function 71 CYP#A# CYP#D# 71 Cancer Vaccines 71 Orphan Status 71 Impairs 71 Inhalation Solution 71 Anti Angiogenesis 71 Zorbtive TM 71 beta 1a 71 Prostate Tumors 71 Ridaforolimus 71 Enlarged Prostate 71 Study Shows Promise 71 Antipsychotic 71 Phase III Pivotal 71 Testosterone Gel 71 Genes Associated 71 Study Proves 71 Adenoviral 71 Inflammatory Disease 71 Ozarelix 71 Skeletal Muscle 71 TRANSDUR ™ 71 Minimally Invasive Treatment 71 Ebola Vaccine 71 Vascular Inflammation 71 Erectile Dysfunction Drug 71 Ranolazine 71 Histone Deacetylase 71 Mycophenolate Mofetil 71 Therapeutic Competitors Report 71 Immunosuppression 71 Prolongs Life 71 Renal Impairment 71 Study Confirms 71 TO AVOID PREGNANCY WHILE 71 Relapsing Remitting Multiple Sclerosis 71 Bevacizumab 71 Regenerative Cells 71 Vildagliptin 71 Monoclonal Antibodies 71 R Saizen R 71 Endometrial Cancer 71 Sirolimus Eluting 71 Premature Infants 71 Tigecycline 71 topical gel formulation 71 Sustained Reduction 71 Genotyping Test 71 Genetic Disorder 71 Vaginal Gel 71 Radiation Induced 71 Male Contraceptive 71 Shingles Vaccine 71 Chronic Bronchitis 71 Insulin Glargine 71 Guidelines Recommend 71 Brain Cells 71 Novel Vaccine 71 ® decitabine 71 Provides Update Regarding 71 Transdermal System 71 Genetic Predisposition 70 Delayed Release 70 ABLYNX 70 ANDA Filing 70 Microplasmin 70 Expand Collaboration 70 Breast Tumors 70 Conjugate 70 Receptor Antagonists 70 Randomized Double Blind Placebo 70 Maleate 70 Ovarian Cancer Patients 70 Capsules CII 70 Chronic Renal Failure 70 Stakeholder Opinions 70 Polyneuropathy 70 Fixed Dose 70 Diuretic 70 Azacitidine 70 Help Predict 70 ALN HPN 70 Obese Patients 70 Lenalidomide 70 investigational oral inhibitor 70 Pivotal Phase II 70 Neuroprotection 70 Statin Therapy 70 Viral Infections 70 Agonist MABA program 70 Chemoradiation 70 Fixed Dose Combination 70 TKB# 70 Hepatitis C Virus 70 Gastrointestinal Disorders 70 Hepatitis B Virus 70 Urine Test 70 Circulating Tumor Cells 70 BiTE Antibody 70 Malignant Glioma 70 Reduces Mortality 70 Results Confirm 70 Doripenem 70 Glufosfamide 70 Receives Positive 70 Bird Flu Vaccine 70 Significant Improvements 70 Irinotecan 70 Leukemia Cells 70 Colorectal Cancer Patients 70 Antisense Oligonucleotides 70 Lung Cancers 70 Myeloid 70 Derma Sciences Announces 70 Endothelial Cells 70 Chronic Inflammation 70 DOR BioPharma Announces 70 Begins Shipment 70 Predict Response 70 Prognostic Value 70 imatinib Gleevec ® 70 Often Misdiagnosed 70 Injection Site 70 Androgen Receptor 70 vapreotide acetate 70 VIVITROL ® 70 Cancer Treatments 70 Faropenem 70 Prove Effective 70 Study Indicates 70 Bucindolol 70 Nitazoxanide 70 Androgen Deprivation Therapy 70 Myelofibrosis 70 Help Detect 70 Pemphigus Vulgaris 70 Gastric Cancer 70 Chemotherapeutic Agents 70 Less Invasive 70 Diabetic Neuropathic Pain 70 VentiRx Pharmaceuticals 70 Genetic Variant 70 Non Invasive Treatment 70 ACE Inhibitors 70 Announcement acc 70 Cognitive Impairment 70 Critically Ill Patients 70 Liver Failure 70 Novel Peptide 70 Immunogenicity 70 PKC# 70 Atypical Antipsychotics 70 Late Breaker 70 Migraine Treatment 70 lexidronam injection 70 Antidepressants Linked 70 Randomized Phase II 70 Genes Predict 70 Commonly Used 70 Atripla combines 70 Randomized Trials 70 Proteasome 70 Neuroprotective Effects 70 PEGylated anti 70 Drug Coated Stent 70 Osteoarthritis Patients 70 Helps Prevent 70 pan HDAC inhibitor 70 Romiplostim 70 Tiotropium 70 gets USFDA nod 70 Respiratory Virus 70 Combination Vaccine 70 Randomized Clinical Trials 70 TRANSDUR ® 70 targeted radiotherapeutic 70 Fentanyl Patch 70 Successfully Completed 70 Generic Protonix 70 Randomized Controlled Trials 70 Androgen Independent 70 Preclinical Evaluation 70 SABER ™ 70 ODT metoclopramide HCl PEPCID 70 Efficacy Results 70 Pandemic Influenza Vaccine 70 Cell Proliferation 70 molecular imaging radiopharmaceutical 70 CysDisplay R 70 Synta Announces 70 Could Predict 70 Randomised Trial 70 Hormone Therapy 70 Oral Anticoagulant 70 Sirolimus Eluting Stent 70 Premenopausal Women 70 Higher Doses 70 Zoledronic Acid 70 microRNA Therapeutics 70 lead molecular radiotherapeutic 70 Breast Cancer Metastasis 70 developing Bicifadine serotonin 70 STELARA TM 70 Controlled Clinical Trial 70 Multiple Sclerosis Rheumatoid Arthritis 70 Signaling Pathways 70 Paliperidone Palmitate 70 Contrast Agents 70 Treat Heart Failure 70 Transcription Factor 70 Avian Influenza Vaccine 70 Treating Heart Failure 70 Proves Successful 70 Contrast Agent 70 Kidney Transplant Recipients 70 Selective Inhibitor 70 Announce Collaboration Agreement 70 Scientists Identify 70 Inhaled Nitric Oxide 70 essential thrombocythemia ET 70 Novel Method 70 Poster Presentations 70 Bone Marrow Cells 70 Seasonal Allergic Rhinitis 70 Oral Cladribine 70 Solid Tumors 70 MKC# MT 70 Study Sheds Light 70 Nuvelo Announces 70 Peginterferon Alfa 2b 70 intranasal formulation 70 Lung Infections 70 Bipolar Depression 70 Immunosuppressant 70 Multicenter Randomized 70 Cardiovascular Outcomes 70 COPEGUS R 70 Nasal Powder 70 Bronchodilator 70 Stomach Cancer 70 Commonly Prescribed 70 Novel Therapies 70 GW# [003] 70 Desvenlafaxine 70 Stem Cell Transplants 70 Poniard Pharmaceuticals Announces 70 Study Shows Significant 70 Denufosol 70 Exclusive License 70 humanized monoclonal 70 Panzem R 70 J Am Coll 70 Detect Cancer 70 Vaccine Adjuvants 70 acetonide FA 70 Hospital Acquired Pneumonia 70 Novel Anticancer 70 Iron Overload 70 Acute Migraine 70 Oncolytic 70 Aloxi ® 70 Capecitabine 70 Could Detect 70 Exercises Option 69 Protein Expression 69 Archexin 69 Prostate Cancer Treatment 69 Pegylated Interferon 69 CHMP Opinion 69 FDA Warns 69 STERIS Corporation Announces 69 Key Milestones 69 refractory chronic lymphocytic 69 k Clearance 69 Aeolus Pharmaceuticals Announces 69 Study Reinforces 69 Hepatitis C Genotype 69 Blood Pressure Drugs 69 Clinically Significant 69 Announce Initiation 69 Hydrochlorothiazide Tablets 69 Non Responders 69 Protects Against 69 Crit Rev 69 GRAS Status 69 Pregnancy Linked 69 Placebo Controlled Study 69 Taxane 69 Influenza Vaccine Production 69 Cancer Stem Cells 69 Febuxostat 69 ORLive Presents 69 R roscovitine CDK cyclin 69 Partial Onset Seizures